Health Archive » March, 2011

Health - March, 2011

292 articles

• J&J Judgment In Stent Patent Suit Climbs To $593M
• Cephalon Investor Sues Over $5.7B Valeant Bid Rebuff
• FDA Panel Calls For More Study On Food Dyes, ADHD
• Coventry Shareholder, ERISA Suits Trimmed
• NY Court Revives Medicor Claims Against UBS Units
• Actavis Pays $10M To Exit Kentucky Medicaid Suit
• US Joins Rural/Metro Ambulance Services FCA Suit
• Judge Lets Yaz Counterclaims Against Bayer Stand
• Agencies Assemble Antitrust Guidance For ACOs
• Swisslog Prevails In McKesson Drug Dispenser IP Suit
• WilmerHale Snatches Howrey, Munger Tolles IP Attys
• Aventis Settles Suit Over Allegra Patent
• Judge Nixes Dismissal Bid In Thalomid Antitrust Suit
• Biolitec Laser Doesn't Infringe AMS Patent: Judge
• Medtronic Didn't Infringe BSC Defibrillator IP: Judge
• GSK Gets $3.5M Verdict In Norvir Antitrust Case
• FDA Weighs Testimony On Health Risks Of Food Dyes
• CDC Probes Bacteria Outbreak From Contaminated IVs
• DC Resident's FCA Claims Killed In Vioxx Fight
• Sanofi Can't Nix Shareholder Suit Over Zimulti
• Novartis, Elan Sue IPC Over Generic Focalin XR
• Generics Makers Ask High Court For State Law Shield
• Pronova, Apotex Strike Deal Over Generic Lovaza
• Paxil Suits Remanded To State Court, To GSK's Chagrin
• Sonova Execs Resign Amid Insider Trading Probe
• Implications Of Nickerson V. Stonebridge
• Sullivan & Cromwell Reps Valeant In $5.7B Cephalon Bid
• Lannett Loses Bid To Enforce Celgene Oral Agreement
• Prosthetics Maker Can't Dodge Antitrust Claims
• Elan, Abbott Settle With Lupin Over Generic TriCor
• J&J Recalls Tylenol Products Amid Odor Concerns
• SEC Says FDA Chemist Made $3.6M In Insider Trading
• Fed. Circ. Fines Sun, Caraco Attys In Eloxatin IP Case
• Pfizer Subsidiary Recalls Mislabeled Drugs
• ProMedica Merger In Ohio Blocked Over Antitrust Fears
• Apotex Must Return $28M Award To Servier: UK Court
• Judge Rules Generic Drug Infringes Dermalogix Patent
• Feds Add Wire, Tax Fraud To Espada Corruption Charges
• Va. AG Tells 4th Circ. Entire Health Care Law Must Go
• Chattem To License LecTec Patch Patents For $3.6M
• FTC OKs $76M Astellas-Maxygen Protein Program Deal
• High Court Kills County's Drug Price Class Action
• An Ounce Of Prevention For Problems With No Cure
• NLRB's Shakeup Of Health Care Bargaining Units
• Cephalon Loses Bid For Quick Win In Marketing Suit
• Merck To Pay $4.2M To End Wis. Medicaid Fight
• Pfizer Beats False Marking Claims
• High Court Seeks US' View In Prandin Use Code Case
• Valuing Noncompetes: The Bradford Decision
• Drugstore.com Investor Fights $409M Walgreen Deal
• Fed. Circ. Revives Watson Challenge Of Seasonique IP
• CORRECTED: FTC OKs Quest's $740M Buyout Of Athena
• Class Rep Pushes To Kill Deal Over Chemo Drug Sales
• Purdue Sues Watson Over Generic OxyContin
• DOJ Expands Blue Cross Blue Shield Antitrust Probe
• Ex-Solicitor General To Rep States In PPACA Fight
• Medtronic Unit Must Face Antitrust Claims: Judge
• Fla. House Committee OKs Malpractice Cap Bill
• NY Commission Won't Probe Conflict In Medicaid Panel
• False Marking Law Found Constitutional In GSK Case
• Wyeth Takes $58M Loss In Hormone Case To High Court
• Group May Make Rival Bid For St. Vincent Facility
• Howmedica Asks High Court To Weigh Polymer IP Case
• 2nd Circ. Affirms Suntrust Win In Defamation Suit
• Cephalon Wins IP Suit Over Watson's Generic Fentora
• Par Sues UCB Over Generic Keppra
• Drug Sales Rep Sues Eisai Over OT Pay
• An Adverse Event For Statistical Significance
• $8.9M Nuvelo Class Action Deal Wins Preliminary OK
• Group Sues HHS For Access To Health Care Ad Info
• ITC Takes Up 337 Probe Of Merck's NuvaRing
• Vermont House Approves Single-Payer Health Care Bill
• Medtronic Unit Settles Faulty Spinal Implant Suit
• J&J Unit Yanks 360K Surgical Drain Products
• Solvay Wants Firms, Expert Removed In AndroGel Suit
• Senate Wants Quarterly Medicare Fraud Reports
• Fed. Circ. Nixes Apotex Appeal In Taxotere IP Fight
• FTC Drops Appeal Of LabCorp Merger Challenge
• Abbott Strikes Deal In Antitrust Battle Over HIV Drugs
• Medtronic, NuVasive Spinal Surgery IP Suit Continues
• 4 Views On Medical Device Preemption
• Jones Day Reps P&G in Joint Venture With Teva
• Sidley, Weil Rep Walgreen In $409M Drugstore.com Buy
• J&J Unit Downplayed Risperdal's Diabetes Link: Jury
• Terumo To Pay $35M Over Heart Device Violations
• Ex-GSK Atty Gets Indictment Over Wellbutrin Tossed
• Abbott, WARF End Zemplar Patent Suit Against Anchen
• Tenet Settles Class Action Over Katrina Deaths
• FTC Blesses Daiichi Sankyo's $805M Plexxikon Buy
• Va. AG Urges High Court To Take Up Health Care Suit
• HIG Picks Up Teleflex's Marine Biz For $122M
• Celera Investor Sues To Block $344M Quest Deal
• Utah University Sues Planck, MIT Over RNA Patents
• Takeda Sues Apotex Over Generic Actos
• Abbott Files New Simcor Patent Suit Against Teva
• HHS Sued Over Health Care Waiver Docs
• Targeting Health Care Antitrust In Texas
• Matrixx Opens Door For Plaintiffs, But Only A Crack
• Pfizer Unit To Exit Ch. 11 With $265M Asbestos Deal
• Watchdog Blasts Insurance Regulators' Industry Ties
• FTC Warns Miss. Lawmakers Over Drug Manager Bill
• Actavis Agrees To Hold Off On Generic Nuvigil
• BSC Can't Shake Contract Claim In Stent Patent Suit
• Sanofi, Merck Drop Animal Health Joint Venture
• Actonel Makers Launch 2nd Suit Over Mylan Generic
• Zuckerman Taps Buc & Beardsley FDA Pros
• Pros And Cons Of Statistical Sampling
• Indicted GSK Atty Says Prosecutors Misled Grand Jury
• Judge Asked To Toss Troutman Atty's Real Estate Suit
• Angiotech Seeks US Approval Of Canada Restructuring
• Holland & Knight Adds Ex-Pol To DC, Fla. Offices
• Female Bayer Workers Launch $100M Sex Bias Suit
• High Court Won't Hear Mylan IP Fight Over Benicar
• Camera-Pill Maker Triumphs In Endoscopy Patent Suit
• Morrison Ruling Doesn't Bar Elan ADR Suit: Judge
• 5 Marketing Lessons From Howrey's Graveside
• Duane Reade Escapes $7M Kasowitz Legal Fee Spat
• 1st Circ. Nixes NeuroMetrix Device Securities Suit
• Mylan Pushes FDA To Rule On Ranbaxy's Lipitor ANDA
• Tenn. Passes Law To Skirt Health Care Mandate
• Recall: Prevent, Manage, Mitigate And Survive
• Medco Sued Over CalPERS Bribery
• Coudert Settles Bard Unit's $25M Malpractice Claim
• Calif. Joins Relator's Kickback Suit V. Bristol-Myers
• Convicted Trader Protests SEC Penalty In 2nd Circ.
• US Sues Teva Over Generic HIV Drug
• SigmaPharm Appeals Skelaxin Antitrust, Contract Suit
• CDC Proposes New HIV Test Timeline For Organ Donors
• Nycomed Faces IP Suit Over Solaraze Gel
• Mich. Can't Sue Merck Over Vioxx, Appeals Court Says
• Orchid Can't Nix Roche Boniva Patent
• Labeling Gaffe Sparks Mylan Drug Recall In Canada
• US Fights Full 11th Circ. Review Of Health Care Law
• FDA Panel Pushes Menthol Cigarette Ban
• Defining The Essential Health Benefits Package
• Shearman Reps Quest Diagnostics In $344M Celera Buy
• Bayer Birth Control Patents Mostly Survive UK Suit
• Doctor Class Loses Cert. In Travelers Fraud Suit
• Insurer Hit With $19M Verdict Over Hospital Coverage
• FDA Head Takes $4.3B Budget Defense To Senate
• ITC Launches 337 Case Over Lilly's Gemzar Patent
• Understanding FTC V. LabCorp.
• The ABCDEFs Of Building Client Loyalty
• Minn. To Pay $7M To End HealthMatch Contract Row
• Class Counsel's Fees Halved In Fla. Insurance Suit
• Pfizer Unit Recalls Pain Drug Embeda
• HHS Readies Health Exchange Guidance For States
• Apotex Doesn't Infringe Provigil Patent, Judge Says
• Braintree Hits Amrutham With Laxative Patent Suit
• Mont. Orders AG To Join Health Care Reform Challenge
• Teva Exits Astellas Patent Suit Over Cancer Drug
• Tekmira Claims Alnylam Stole Gene Therapy Secrets
• Baxter Pockets Partial Costs In ERISA Win
• Triad Halts Production Of Pads Tied To Child's Death
• Premier Wins Bid To Arbitrate Rival's Antitrust Suit
• Endo Sues Mylan Over Generic Lidoderm Patch
• NY Assembly Challenges Cuomo's Malpractice Cap
• Cephalon Tries To Nix Approval For Generic Fentora
• Obama Accused Of Passing Health Law Regs In Secret
• 9th Circ. Refuses To Freeze $58M LabCorp Merger
• House Bill Would Ax Medicare Bidding Program
• Alnylam, German Group Settle RNA Patent App Case
• Latham Reps DJO In $254M Dr. Comfort Acquisition
• Gilead, Roche Sue To Block Generic Tamiflu
• IP Official Recommends Stronger Enforcement Plan
• DOJ Contests Va. Health Care Law Appeal
• Pa. Action Over Dead Health Care Plan Targets Pols
• Rite Aid Managers Take OT Actions To 3rd Circ.
• AstraZeneca Says SC Seroquel Suit Is Money Grab
• Guatemalans Infected With Syphilis Want US To Pay
• Fed. Circ. Won't Revisit Abraxis Loss In Naropin Suit
• Ex-Exactech Director Avoids Prison In Kickback Case
• One For The 'Have Nots'
• Troubleshooting Calif.'s Health Benefit Exchange
• Ropes & Gray Lures Life Sciences Atty From Goodwin
• St. Vincent's To Sell Manhattan Hospital For $260M
• CORRECTED: Medline To Pay $91M Over Medicare Kickback Suit
• Watson Wins Invalidity Ruling On 2 Fentora Patents
• Aventis, Sandoz Drop Swords In Taxotere Patent Suit
• 11th Circ. Fast-Tracks Health Care Reform Fight
• 2nd Circ. Kills B&L Indemnity Bid, Not Defense Claim
• Minn. Pharmacy Class Suit Wrongly Remanded: 8th Circ.
• FDA Chief Backs $4.3B Budget In House Hearing
• A Shot In The Arm For Section 2 Enforcement
• Patients Sue Genzyme Over Fabrazyme Rationing
• J&J Unit Agrees To Stop Making Drugs At Pa. Plant
• Ex-WellCare Execs Plead Not Guilty To Medicaid Fraud
• Ex-KV CEO Gets 1 Month, $1M Fine For False Drug Marks
• HHS Proposes New State Health Care Waiver Rules
• UBS Touted Fraudulent Medicore Investments: Atty
• NY Legislators, Hospital CEOs Charged With Bribery
• EU Embryo Patent Ban Covers Stem Cells: Court Adviser
• Vista Dodges Bulk Of Ex-Worker's Medicaid FCA Suit
• Becton Asks Fed. Circ. To Chuck $5M Syringe IP Loss
• Merchant & Gould Adds Hatch-Waxman Guru To IP Team
• AstraZeneca Seeks To Block Ex-Consultant's Testimony
• AstraZeneca To Pay $69M To States Over Seroquel
• Judge Certifies Mass. Class In CVS False Ad Suit
• Not So Sweet 16
• Generics Maker Sues 3M In Skin Cream Row
• MedAssets Seeks Discovery Sanctions In Insurance Row
• NC Lawmakers Fail To Pass Health Care Law Protest
• Health Care Law Can Buffer Improper CMS Costs: GAO
• 7th Circ. Tosses Qui Tam Suit Over Wordy Brief
• NY Hospital Workers Win Class Cert. Over Meal Breaks
• American Capital Can't Nix Insurers' Heparin Suit
• Tort Reform Group Sees Conflict In Cuomo Panel
• Houston Medical Supplier Convicted Of $4.3M Fraud
• Allergan, Rivals Debate Competition Claims' Validity
• Child Deaths Not Linked To Vaccines: Japan Drug Panel
• BSC, St. Jude Reach Deal Over Sales Exec Noncompete
• Ex-Best Medical Workers Slip Cancer Therapy IP Suit
• FTC Clears Danaher's Beckman Buy But Hurdles Remain
• United Health Seeks To Revive $28M Insurance Claim
• Fla. Judge Backs Contract For Prescription Program
• Latham Reps Catalyst In $525M Walgreen Unit Buy
• State AGs Support Health Care Law At 4th Circ.
• Antitrust Risks For ACOs
• US Appeals Fla. Ruling Against Health Care Reform Law
• UnitedHealth, Lawmakers Bash $24B Humana Contract
• Arrow, J&J Liability Claims Preempted: 11th Circ.
• Kaiser Unit To Settle OT Class Action For $1.1M
• Guatemalan Syphilis Subjects Set Class Action Deadline
• FDA Warns Of Risks To Babies From HIV Drug Kaletra
• Fed. Circ. Kills Mylan's Prilosec Antitrust Claims
• FTC Blesses GTCR's $675M Purchase Of Sterigenics
• 200 NY Attorneys Back Cuomo's Malpractice Overhaul
• GSK Sales Reps Seek 9th Circ. Rehearing On OT Status
• Fueling The BPCI Debate
• Woman Pleads Guilty To Wheelchair Fraud Scheme
• Tennessee House Passes Bill To Curb PPACA Mandates
• Drugmakers Beat Price-Fixing Claims In Ca. Court
• BNY, Wells Fargo OK'd To Intervene In $21M Ponzi Deal
• German Court Affirms Void Of Medix Testing Patent
• Caremark Can't Ditch Contract Claims In Coventry Suit
• Gibson Dunn Reps Accuray In $277M Radiotherapy Deal
• Generics Co. Asks Fed. Circ. To Revive Fortican Claims
• Bovie, Medtronic Settle IP Suit Over Surgical Device
• Watson, Orchid Defenses Live In Generic Azilect Row
• AstraZeneca, Mylan Spar Over Prilosec Suit Dismissal
• High Court Denies Cert In Biopsy Tool Patent Suit
• Supreme Court Spurns Investigation Retaliation Case
• MoFo Reps Terumo In $2.6B Gambro Unit Deal
• Japan Halts Pfizer, Sanofi Pediatric Vaccines
• Maximizing Your Chance At Federal Dollars
• Top Court Refuses To Hear Pay-For-Delay Challenge
• Gov'ts Win Cert. In McKesson Price-Rigging Suit
• Texas Judge Won't Move Aso Bandage Patent Case
• Mylan, Others Hit With Class Action Over Painkillers
• Trial Date Set In Ex-NY State Sen.'s Corruption Case
• Blackstone Sues Taro For $6M In Unpaid Merger Fees
• Drug Supply Co. Fraud Suit Referred To Mediation
• Cephalon Bid For Apotex Docs Denied In Provigil Suit
• Occlutech Implants Don't Violate IP: Swedish Court
• Sterilizer Co. To Pay $20M In Medical Device Action
• Ex-Cyberonics CEO Defies Options Reports In 2nd Circ.
• Merck Must Face Unjust Firing Suit, 1st Circ. Rules
• UnitedHealth Hit With ERISA Class Action
• Group Sues For Access To Kagan Health Care Law Docs
• GOP Brings Back Medical Malpractice Reform Bill
• FDA To Up Topamax Warning Over Birth Defect Data
• Paul Hastings Reps Valitas In $250M Merger
• Ex-WellCare CEO, Others Charged With Medicaid Fraud
• Cigna Worker Launches $100M Sex Bias Action
• Immunizing Vaccine Manufacturers From State Claims
• Allergan Tries To Nix Breast Implant Marking Suit
• Merck Settles Trade Secrets Row Over Software
• Fla. Judge Stays Toss Of Federal Health Care Reform
• J&J's Ethicon Unit Reveals Surgical Suture Recall
• Blue Cross Slaps Hofstra, Hospital With Logo IP Suit
• Sens. Clash Over 1st-To-File Patent Plan
• Suit Against $3B EMS Sale Targets BofA Merrill Lynch
• McKesson Fights $212M Ariz. Fine Over Drug Prices
• Fulbright Picks Up 2 Litigators For LA Office
• Senate Probes New Tools For Medicare Fraud Fight
• Neuralstem Calls StemCells Patents 'Unenforceable'
• Insurers Freed From Tissue Donation Coverage Suit
• Shareholder Seeks To Halt $1.2B Clinical Data Sale
• FDA Cracks Down On Unapproved Cold, Cough Drugs
• Merck, Teva End Cancidas Patent Fight
• Calling For Clarity On Conflict Metals
• Astellas Sued Over Efforts To Block Generic Prograf
• Pay-For-Delay Deals Stay Under Wraps In Cephalon Suit
• FTC Gives Green Light To $1.25B CVS-Universal Deal
• Genentech Nears $2.6M Deal In IT Workers' OT Suit
• KemPharm Hits Shire With Antitrust Counterclaims
• NIH To Study Health Of BP Spill Cleanup Workers
• Allergan's Acadia Securities Sales Spark SEC Subpoenas
• Simpson Reps Daiichi Sankyo In $805M Plexxikon Buy
• GenMark Drops Suit Over Caliper Microfluidics Patents
• ClearCorrect Faces IP, Competition Suits Over Braces
• Issues In HIE Creation And Participation